Bio-Rad Laboratories, Inc. (BIO) PS Ratio: 3.09
Is Bio-Rad Laboratories, Inc.’s P/S ratio high or low?
Bio-Rad Laboratories, Inc.'s P/S ratio of 3.09 is 29% below its 5-year average of 4.33, near the low end of its 5-year range (2.38–8.64).
The P/S ratio for Bio-Rad Laboratories, Inc. (BIO) is 3.09 as of Tuesday, June 9, 2026. It is above its 12-month average by 2.43% (3.02).
BIO PS Ratio Chart
BIO Average PS Ratio Chart
BIO Current vs Average PS Ratio Chart
BIO PS Ratio Metrics
PS RATIO
3.09
PS RATIO AVG TTM
3.02
PS RATIO AVG 3Y
3.31
PS RATIO AVG 5Y
4.33
PS RATIO AVG 10Y
4.31
PS RATIO AVG 15Y
3.43
PS RATIO AVG 20Y
2.95
CURRENT VS TTM AVG
+2.43%
CURRENT VS 3Y AVG
-6.72%
CURRENT VS 5Y AVG
-28.72%
CURRENT VS 10Y AVG
-28.37%
CURRENT VS 15Y AVG
-9.80%
CURRENT VS 20Y AVG
+4.72%
BIO Competitors' PS Ratio
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | — | 3.09 | 3.02 | 3.31 | 4.33 |
| Charles River Laboratories International, Inc. (CRL) | $9.14B | 2.31 | 2.13 | 2.36 | 3.08 |
| Hims & Hers Health, Inc. (HIMS) | $6.46B | 2.79 | 4.56 | 4.20 | 4.38 |
| Align Technology, Inc. (ALGN) | $12.76B | 3.11 | 2.94 | 4.29 | 6.16 |
| Hologic, Inc. (HOLX) | $16.97B | 4.16 | 3.83 | 4.27 | 3.99 |
| Moderna, Inc. (MRNA) | $18.94B | 8.47 | 6.08 | 5.19 | 7.14 |
| BioNTech SE (BNTX) | $21.87B | 7.82 | 8.42 | 7.38 | 6.08 |
| Mettler-Toledo International Inc. (MTD) | $23.50B | 5.77 | 6.81 | 6.98 | 7.68 |
| Waters Corporation (WAT) | $24.19B | 8.09 | 6.60 | 6.57 | 6.83 |
| Veeva Systems Inc. (VEEV) | $27.37B | 8.39 | 13.09 | 13.77 | 16.20 |
P/S vs. its own history
At 3.09, P/S is in its normal range — richer than 60% of its 20-year range.
20-year low
0.83
median
2.11
20-year high
8.64
Sales Valuation
P/S Ratio
3.09
Market Cap / Annual Revenue
Bio-Rad Laboratories, Inc. PS Ratio Formula & Definition
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. PS Ratio FAQ
- What is the P/S ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The P/S ratio for BIO stock is 3.09.
- Is Bio-Rad Laboratories, Inc.'s P/S ratio high or low?
- Bio-Rad Laboratories, Inc.'s P/S ratio of 3.09 is 29% below its 5-year average of 4.33, near the low end of its 5-year range (2.38–8.64).
- What is the TTM average P/S ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average P/S ratio for BIO stock is 3.02.
- What is the 3Y average P/S ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average P/S ratio for BIO stock is 3.31.
- What is the 5Y average P/S ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average P/S ratio for BIO stock is 4.33.
- What is the 10Y average P/S ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average P/S ratio for BIO stock is 4.31.
- What is the 15Y average P/S ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average P/S ratio for BIO stock is 3.43.
- What is the 20Y average P/S ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average P/S ratio for BIO stock is 2.95.
Bio-Rad Laboratories, Inc. PS Ratio History
| DATE | PS RATIO |
|---|---|
| 2026-06-03 | 3.17 |
| 2026-06-02 | 3.19 |
| 2026-06-01 | 3.18 |
| 2026-05-29 | 3.25 |
| 2026-05-28 | 3.31 |
| 2026-05-27 | 3.18 |
| 2026-05-26 | 3.09 |
| 2026-05-22 | 3.00 |
| 2026-05-21 | 2.98 |
| 2026-05-20 | 3.00 |
| 2026-05-19 | 2.93 |
| 2026-05-18 | 2.93 |
| 2026-05-15 | 2.58 |
| 2026-05-14 | 2.56 |
| 2026-05-13 | 2.53 |
| 2026-05-12 | 2.52 |
| 2026-05-11 | 2.54 |
| 2026-05-08 | 2.65 |
| 2026-05-07 | 2.68 |
| 2026-05-06 | 2.70 |
| 2026-05-05 | 2.68 |
| 2026-05-04 | 2.68 |
| 2026-05-01 | 2.67 |
| 2026-04-30 | 2.92 |
| 2026-04-29 | 2.88 |
| 2026-04-28 | 2.92 |
| 2026-04-27 | 3.00 |
| 2026-04-24 | 3.01 |
| 2026-04-23 | 2.94 |
| 2026-04-22 | 3.15 |
| 2026-04-21 | 3.20 |
| 2026-04-20 | 3.17 |
| 2026-04-17 | 3.13 |
| 2026-04-16 | 3.04 |
| 2026-04-15 | 3.09 |
| 2026-04-14 | 3.06 |
| 2026-04-13 | 3.01 |
| 2026-04-10 | 2.92 |
| 2026-04-09 | 2.90 |
| 2026-04-08 | 2.94 |
| 2026-04-07 | 2.91 |
| 2026-04-06 | 2.92 |
| 2026-04-02 | 2.93 |
| 2026-04-01 | 2.91 |
| 2026-03-31 | 2.91 |
| 2026-03-30 | 2.83 |
| 2026-03-27 | 2.78 |
| 2026-03-26 | 2.89 |
| 2026-03-25 | 2.86 |
| 2026-03-24 | 2.85 |
| 2026-03-23 | 2.77 |
| 2026-03-20 | 2.77 |
| 2026-03-19 | 2.77 |
| 2026-03-18 | 2.80 |
| 2026-03-17 | 2.82 |
| 2026-03-16 | 2.73 |
| 2026-03-13 | 2.75 |
| 2026-03-12 | 2.74 |
| 2026-03-11 | 2.82 |
| 2026-03-10 | 2.80 |
| 2026-03-09 | 2.84 |
| 2026-03-06 | 2.82 |
| 2026-03-05 | 2.92 |
| 2026-03-04 | 2.98 |
| 2026-03-03 | 2.93 |
| 2026-03-02 | 2.92 |
| 2026-02-27 | 2.91 |
| 2026-02-26 | 2.88 |
| 2026-02-25 | 2.82 |
| 2026-02-24 | 2.81 |
| 2026-02-23 | 2.81 |
| 2026-02-20 | 2.84 |
| 2026-02-19 | 2.84 |
| 2026-02-18 | 2.83 |
| 2026-02-17 | 2.77 |
| 2026-02-13 | 2.68 |
| 2026-02-12 | 3.06 |
| 2026-02-11 | 3.09 |
| 2026-02-10 | 3.16 |
| 2026-02-09 | 3.10 |
| 2026-02-06 | 3.17 |
| 2026-02-05 | 3.15 |
| 2026-02-04 | 3.22 |
| 2026-02-03 | 3.15 |
| 2026-02-02 | 3.13 |
| 2026-01-30 | 3.09 |
| 2026-01-29 | 3.10 |
| 2026-01-28 | 3.16 |
| 2026-01-27 | 3.13 |
| 2026-01-26 | 3.15 |
| 2026-01-23 | 3.12 |
| 2026-01-22 | 3.21 |
| 2026-01-21 | 3.28 |
| 2026-01-20 | 3.29 |
| 2026-01-16 | 3.30 |
| 2026-01-15 | 3.39 |
| 2026-01-14 | 3.35 |
| 2026-01-13 | 3.39 |
| 2026-01-12 | 3.40 |
| 2026-01-09 | 3.41 |
| 2026-01-08 | 3.36 |
| 2026-01-07 | 3.41 |
| 2026-01-06 | 3.43 |
| 2026-01-05 | 3.39 |
| 2026-01-02 | 3.21 |
| 2025-12-31 | 3.19 |
| 2025-12-30 | 3.21 |
| 2025-12-29 | 3.20 |
| 2025-12-26 | 3.20 |
| 2025-12-24 | 3.18 |
| 2025-12-23 | 3.17 |
| 2025-12-22 | 3.21 |
| 2025-12-19 | 3.17 |
| 2025-12-18 | 3.16 |
| 2025-12-17 | 3.17 |
| 2025-12-16 | 3.18 |
| 2025-12-15 | 3.24 |
| 2025-12-12 | 3.24 |
| 2025-12-11 | 3.31 |
| 2025-12-10 | 3.32 |
| 2025-12-09 | 3.24 |
| 2025-12-08 | 3.25 |
| 2025-12-05 | 3.34 |
| 2025-12-04 | 3.37 |
| 2025-12-03 | 3.37 |
| 2025-12-02 | 3.35 |
| 2025-12-01 | 3.38 |
| 2025-11-28 | 3.42 |
| 2025-11-26 | 3.44 |
| 2025-11-25 | 3.50 |
| 2025-11-24 | 3.39 |
| 2025-11-21 | 3.33 |
| 2025-11-20 | 3.20 |
| 2025-11-19 | 3.21 |
| 2025-11-18 | 3.24 |
| 2025-11-17 | 3.20 |
| 2025-11-14 | 3.30 |
| 2025-11-13 | 3.34 |
| 2025-11-12 | 3.45 |
| 2025-11-11 | 3.30 |
| 2025-11-10 | 3.24 |
| 2025-11-07 | 3.22 |
| 2025-11-06 | 3.23 |
| 2025-11-05 | 3.26 |
| 2025-11-04 | 3.27 |
| 2025-11-03 | 3.28 |
| 2025-10-31 | 3.36 |
| 2025-10-30 | 3.21 |
| 2025-10-29 | 3.36 |
| 2025-10-28 | 3.52 |
| 2025-10-27 | 3.58 |
| 2025-10-24 | 3.62 |
| 2025-10-23 | 3.61 |
| 2025-10-22 | 3.56 |
| 2025-10-21 | 3.53 |
| 2025-10-20 | 3.43 |
| 2025-10-17 | 3.30 |
| 2025-10-16 | 3.33 |
| 2025-10-15 | 3.26 |
| 2025-10-14 | 3.25 |
| 2025-10-13 | 3.24 |
| 2025-10-10 | 3.17 |
| 2025-10-09 | 3.20 |
| 2025-10-08 | 3.23 |
| 2025-10-07 | 3.16 |
| 2025-10-06 | 3.30 |
| 2025-10-03 | 3.26 |
| 2025-10-02 | 3.14 |
| 2025-10-01 | 3.18 |
| 2025-09-30 | 2.99 |
| 2025-09-29 | 2.88 |
| 2025-09-26 | 2.89 |
| 2025-09-25 | 2.88 |
| 2025-09-24 | 2.95 |
| 2025-09-23 | 3.01 |
| 2025-09-22 | 3.02 |
| 2025-09-19 | 3.03 |
| 2025-09-18 | 3.05 |
| 2025-09-17 | 2.99 |
| 2025-09-16 | 3.01 |
| 2025-09-15 | 2.99 |
| 2025-09-12 | 2.99 |
| 2025-09-11 | 3.05 |
| 2025-09-10 | 2.95 |
| 2025-09-09 | 3.05 |
| 2025-09-08 | 3.10 |
| 2025-09-05 | 3.15 |
| 2025-09-04 | 3.09 |
| 2025-09-03 | 3.07 |
| 2025-09-02 | 3.10 |
| 2025-08-29 | 3.18 |
| 2025-08-28 | 3.13 |
| 2025-08-27 | 3.12 |
| 2025-08-26 | 3.16 |
| 2025-08-25 | 3.17 |
| 2025-08-22 | 3.24 |
| 2025-08-21 | 3.04 |
| 2025-08-20 | 3.07 |
| 2025-08-19 | 3.07 |
| 2025-08-18 | 3.03 |
| 2025-08-15 | 3.05 |
| 2025-08-14 | 3.06 |
| 2025-08-13 | 3.06 |
| 2025-08-12 | 2.93 |
| 2025-08-11 | 2.82 |
| 2025-08-08 | 2.82 |
| 2025-08-07 | 2.83 |
| 2025-08-06 | 2.82 |
| 2025-08-05 | 2.90 |
| 2025-08-04 | 2.95 |
| 2025-08-01 | 3.03 |
| 2025-07-31 | 2.58 |
| 2025-07-30 | 2.75 |
| 2025-07-29 | 2.78 |
| 2025-07-28 | 2.79 |
| 2025-07-25 | 2.91 |
| 2025-07-24 | 2.88 |
| 2025-07-23 | 2.83 |
| 2025-07-22 | 2.70 |
| 2025-07-21 | 2.69 |
| 2025-07-18 | 2.71 |
| 2025-07-17 | 2.75 |
| 2025-07-16 | 2.72 |
| 2025-07-15 | 2.72 |
| 2025-07-14 | 2.76 |
| 2025-07-11 | 2.83 |
| 2025-07-10 | 2.86 |
| 2025-07-09 | 2.78 |
| 2025-07-08 | 2.76 |
| 2025-07-07 | 2.72 |
| 2025-07-03 | 2.77 |
| 2025-07-02 | 2.76 |
| 2025-07-01 | 2.73 |
| 2025-06-30 | 2.65 |
| 2025-06-27 | 2.68 |
| 2025-06-26 | 2.68 |
| 2025-06-25 | 2.65 |
| 2025-06-24 | 2.62 |
| 2025-06-23 | 2.59 |
| 2025-06-20 | 2.60 |
| 2025-06-18 | 2.55 |
| 2025-06-17 | 2.54 |
| 2025-06-16 | 2.55 |
| 2025-06-13 | 2.50 |
| 2025-06-12 | 2.56 |
| 2025-06-11 | 2.53 |
| 2025-06-10 | 2.54 |
| 2025-06-09 | 2.48 |
| 2025-06-06 | 2.41 |
| 2025-06-05 | 2.41 |
| 2025-06-04 | 2.44 |
| 2025-06-03 | 2.43 |
| 2025-06-02 | 2.38 |
| 2025-05-30 | 2.50 |
| 2025-05-29 | 2.50 |
| 2025-05-28 | 2.52 |
| 2025-05-27 | 2.53 |
| 2025-05-23 | 2.46 |
| 2025-05-22 | 2.50 |
| 2025-05-21 | 2.51 |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz